Immunic Inc. (IMUX) Announces Proposed Common Share Offering

Immunic, Inc. (NASDAQ: IMUX) today announced it has commenced a public offering of shares of its common stock.

Immunic intends to use the proceeds from the offering to fund the ongoing clinical development of the Company's three small molecule products: IMU-838, IMU-935 and IMU-856, and for other general corporate purposes, including to investigate IMU-838, the Company's lead asset, as a potential oral treatment option for COVID-19.

Roth Capital Partners is acting as a placement agent in connection with the offering.

The shares of common stock will be offered pursuant to a shelf registration statement on Form S-3 (File No. 333-225230), which was declared effective by the United States Securities and Exchange Commission (SEC) on June 13, 2018.

The pricing of the shares of common stock will be determined in the course of marketing, and there can be no assurance as to whether or when the offering will be completed, or as to the actual size or terms of the offering.

You May Also Be Interested In

• AppFolio board sees departures and new appointments
• Finance of America acquires $5.2B in reverse mortgage assets from Onity
• Ares Acquisition Corporation III raises $395M in NYSE IPO